Gabriele Giuliano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gabriele Giuliano has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Mario Tumbarello
Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy
3 shared publications- Mario Tumbarello
Department of Medical Biotechnologies, University of Siena , Siena
3 shared publications Margherita Sambo
Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy
2 shared publications- Margherita Sambo
Department of Medical Biotechnologies, University of Siena, Siena, Italy
2 shared publications Sara Benedetti
Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy
2 shared publicationsAlberto Michielon
School of Specialization in Hospital Pharmacy, University of Siena, Siena, Italy
1 shared publication
Latest Publications
- 5 February 2026
- Published by Elsevier in Enfermedades Infecciosas y Microbiologia Clinica (English Ed.)
- Vol. 44 (2) , 503053
Management of infections caused by Gram-negative bacteria in severely immunocompromised hosts employing Outpatient Parenteral Antimicrobial Therapy (OPAT): Preliminary evidence from a real-world observational study
- 5 February 2026
- Published by Elsevier in Enfermedades Infecciosas y Microbiologia Clinica (English Ed.)
- Vol. 44 (2) , 503053
Management of infections caused by Gram-negative bacteria in severely immunocompromised hosts employing Outpatient Parenteral Antimicrobial Therapy (OPAT): Preliminary evidence from a real-world observational study
- 19 December 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (4) , 1177-1184
Treatment of post-lung transplantation pneumonia with cefiderocol: a case series and insights from the literature
Background: Post-lung transplantation pneumonia (pLuTP) is among the most frequent complications following lung transplantation, predominantly caused by Gram-negative bacteria (GNB). The emergence of multidrug-resistant (MDR) non-fermenting GNB as aetiological agents of pLuTP represents a major therapeutic challenge due to limited treatment options. Methods: We present a retrospective case series describing 20 episodes of pLuTP successfully treated with cefiderocol. Results: Thirteen patients, with a median age of 56 years (IQR 44–59), experienced a total of 20 episodes of pLuTP. In 3 cases (25.0%), polymicrobial pneumonia was diagnosed. Acinetobacter baumannii was isolated in 13/20 episodes (65.0%), followed by Pseudomonas aeruginosa (6/20, 30.0%), Achromobacter xylosoxidans and Klebsiella pneumoniae (2/20, 10.0% each). Cefiderocol was administered in all episodes: as monotherapy in 5/20 cases (25.0%), in combination with high-dose ampicillin/sulbactam in 7/20 cases (35.0%), aminoglycosides or intravenous colistin (2/20, 10.0% each), and other regimens in the remaining 4/20 cases (20.0%). Clinical cure was achieved in 17/20 cases (85.0%). Microbiological eradication was not achieved in any case. Relapse occurred in 4/20 episodes (20.0%), with no evidence of in vitro cefiderocol resistance. No major adverse events were reported. Conclusions: Cefiderocol may represent a valuable therapeutic option for managing pLuTP caused by difficult-to-treat GNB in lung transplant recipients.
- 19 December 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (4) , 1177-1184
Treatment of post-lung transplantation pneumonia with cefiderocol: a case series and insights from the literature
Background: Post-lung transplantation pneumonia (pLuTP) is among the most frequent complications following lung transplantation, predominantly caused by Gram-negative bacteria (GNB). The emergence of multidrug-resistant (MDR) non-fermenting GNB as aetiological agents of pLuTP represents a major therapeutic challenge due to limited treatment options. Methods: We present a retrospective case series describing 20 episodes of pLuTP successfully treated with cefiderocol. Results: Thirteen patients, with a median age of 56 years (IQR 44–59), experienced a total of 20 episodes of pLuTP. In 3 cases (25.0%), polymicrobial pneumonia was diagnosed. Acinetobacter baumannii was isolated in 13/20 episodes (65.0%), followed by Pseudomonas aeruginosa (6/20, 30.0%), Achromobacter xylosoxidans and Klebsiella pneumoniae (2/20, 10.0% each). Cefiderocol was administered in all episodes: as monotherapy in 5/20 cases (25.0%), in combination with high-dose ampicillin/sulbactam in 7/20 cases (35.0%), aminoglycosides or intravenous colistin (2/20, 10.0% each), and other regimens in the remaining 4/20 cases (20.0%). Clinical cure was achieved in 17/20 cases (85.0%). Microbiological eradication was not achieved in any case. Relapse occurred in 4/20 episodes (20.0%), with no evidence of in vitro cefiderocol resistance. No major adverse events were reported. Conclusions: Cefiderocol may represent a valuable therapeutic option for managing pLuTP caused by difficult-to-treat GNB in lung transplant recipients.
- Open Access
- 11 June 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 44, 116-126
Urinary tract infections caused by Gram-negative bacteria in elderly hospitalized patients: Epidemiology, clinical features and outcomes in the era of antimicrobial resistance
- 11 June 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 44, 116-126
Open AccessUrinary tract infections caused by Gram-negative bacteria in elderly hospitalized patients: Epidemiology, clinical features and outcomes in the era of antimicrobial resistance
- 12 November 2024
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (1) , 193-196
Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant K. pneumoniae shunt-related ventriculitis: two case reports and review of the literature
Recently, an increase in cases of multidrug-resistant Gram-negative bacteria post-neurosurgical ventriculitis and meningitis is reported. Treating these infections has become challenging due to the limited availability of antibiotics and the need to select those with optimal pharmacodynamic and pharmacokinetic profiles. There is limited evidence regarding the use of meropenem-vaborbactam in treating carbapenem-resistant Enterobacterales infections of the central nervous system. We report two new cases of shunt-related ventriculitis due to carbapenem-resistant K.pneumoniae with a favorable microbiological evolution after IV only combination therapy with meropenem-vaborbactam.
- 12 November 2024
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (1) , 193-196
Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant K. pneumoniae shunt-related ventriculitis: two case reports and review of the literature
Recently, an increase in cases of multidrug-resistant Gram-negative bacteria post-neurosurgical ventriculitis and meningitis is reported. Treating these infections has become challenging due to the limited availability of antibiotics and the need to select those with optimal pharmacodynamic and pharmacokinetic profiles. There is limited evidence regarding the use of meropenem-vaborbactam in treating carbapenem-resistant Enterobacterales infections of the central nervous system. We report two new cases of shunt-related ventriculitis due to carbapenem-resistant K.pneumoniae with a favorable microbiological evolution after IV only combination therapy with meropenem-vaborbactam.
- Open Access
- 6 April 2023
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 61 (6) , 106806
Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey
- 6 April 2023
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 61 (6) , 106806
Open AccessBloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey